2022 - Research.com Microbiology in Belgium Leader Award
2010 - Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson for his landmark discoveries in anti-HIV medications, including nucleotide analogues, and inventions or co-inventions of several approved drugs for anti-viral therapy.
1994 - Fellow of the American Association for the Advancement of Science (AAAS)
1989 - Member of Academia Europaea
Erik De Clercq focuses on Virology, Virus, Stereochemistry, Molecular biology and Biochemistry. His Virology research includes themes of Reverse transcriptase and Immunology. His Reverse transcriptase research incorporates themes from Nevirapine and Drug resistance.
His study brings together the fields of Microbiology and Virus. His research in Stereochemistry intersects with topics in Biological activity, Structure–activity relationship, Chemical synthesis and Enzyme inhibitor. His studies deal with areas such as Cell culture, Integrase, DNA, Chemokine and CC chemokine receptors as well as Molecular biology.
His main research concerns Stereochemistry, Virology, Virus, Biochemistry and Reverse transcriptase. His Stereochemistry research incorporates elements of Biological activity, Structure–activity relationship and Chemical synthesis. Erik De Clercq interconnects Bicyclic molecule, Enzyme inhibitor and Reverse-transcriptase inhibitor in the investigation of issues within Chemical synthesis.
Erik De Clercq has researched Virology in several fields, including Molecular biology and In vitro. Erik De Clercq does research in Virus, focusing on Vesicular stomatitis virus specifically. His Reverse transcriptase study combines topics from a wide range of disciplines, such as Mutant and Enzyme.
Erik De Clercq mostly deals with Stereochemistry, Reverse transcriptase, Virology, Mutant and Combinatorial chemistry. As a part of the same scientific study, Erik De Clercq usually deals with the Stereochemistry, concentrating on Structure–activity relationship and frequently concerns with Cell culture. His Reverse transcriptase study integrates concerns from other disciplines, such as Nevirapine, EC50 and Potency.
The study incorporates disciplines such as Pharmacology and Nucleoside in addition to Virology. His Mutant research includes elements of Mutation, Molecular biology, Docking and Enzyme. His research on Virus concerns the broader Immunology.
Erik De Clercq mainly focuses on Stereochemistry, Virology, Reverse transcriptase, Nucleoside Reverse Transcriptase Inhibitor and Diarylpyrimidines. The various areas that he examines in his Stereochemistry study include Combinatorial chemistry, Delavirdine and Structure–activity relationship. His studies in Virology integrate themes in fields like Immunology, Pharmacology and Nucleoside.
His Reverse transcriptase research is multidisciplinary, incorporating perspectives in EC50, Biological activity, Docking and Strain. His Pyrimidine research is multidisciplinary, incorporating elements of Aryl and In vitro. His Virus research integrates issues from Favipiravir and BCX4430.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Rudi Pauwels;Jan Balzarini;Masanori Baba;Robert Snoeck.
Journal of Virological Methods (1988)
Angiogenesis : regulators and clinical applications
Sandra Liekens;Erik De Clercq;Johan Neyts.
Biochemical Pharmacology (2001)
A novel selective broad-spectrum anti-DNA virus agent.
Erik De Clercq;Antonin Holý;Ivan Rosenberg;Takashi Sakuma.
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
Rudi Pauwels;Koen Andries;Jan Desmyter;Dominique Schols.
Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections.
Erik De Clercq.
Journal of Medicinal Chemistry (1995)
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Dominique Schols;Sofie Struyf;Jo Van Damme;José A. Esté.
Journal of Experimental Medicine (1997)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Guangdi Li;Erik De Clercq.
Nature Reviews Drug Discovery (2020)
Approved Antiviral Drugs over the Past 50 Years
Erik De Clercq;Guangdi Li;Guangdi Li.
Clinical Microbiology Reviews (2016)
Antiviral agents active against influenza A viruses
Erik De Clercq.
Nature Reviews Drug Discovery (2006)
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
Erik De Clercq.
International Journal of Antimicrobial Agents (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: